Genesis Therapeutics is pioneering artificial intelligence guided rational drug design to address severe unmet medical needs for patients. Our lab in San Diego is looking for a motivated and versatile Drug Metabolism and Pharmacokinetics (DMPK) Principal Scientist or Associate Director to join our team to help advance our compounds through preclinical and clinical development. The successful candidate will be driving the overall PKPD modeling and simulation (M&S) effort to support projects from early research through early clinical development.
This is a full-time position in a fast-paced biotech environment with a collegial group of high-level colleagues working towards well-defined goals. Full medical and dental benefits, flexible work hours/vacation included in this opportunity to learn all aspects of biotech start-up.
Learn more about us here:https://www.genesistherapeutics.ai/
And our recent collaboration with Eli Lilly here:
About Genesis Therapeutics
Genesis Therapeutics is a pioneering AI Biotech company focusing on the discovery of novel drugs using unique approaches to both undrugged and underdeveloped targets with the goal of providing new treatments for patients with severe diseases.
Genesis has raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. In addition, Genesis has announced two AI platform collaborations across a range of therapeutic areas with Genentech and h Eli Lilly, the latter of which entailed a $20M upfront payment with a $670M total deal size. We’ve also been featured in Forbes 30u30 and in Forbes AI 50.
Genesis originated in graph machine learning research in Vijay Pande’s lab at Stanford, when it was joined by legendary drug hunters and biotech entrepreneurs (including Dr. Leonard Bell, founder and CEO of Alexion Pharmaceuticals, acquired by Astra Zeneca for $39Bn; and Peppi Prasit, storied chemist from Merck known for Vioxx, Arcoxia, Singulair, who then went on to found Amira Pharmaceuticals, acquired by BMS, and Inception Sciences). The company is making strong progress in expanding the domain of our AI technology with the advance of our pipeline of best-in-class and first-in-class programs, both internal targets and those in partnership with Genentech and Lilly.
Subscribe to Rise newsletter